Previous Events

Steve Fodor PhD, Founder of Affymetrix

"From Science to Industry: The story of the microarray"



Event Date: Wednesday, April 27, 2011, 6:00 pm to 7:30 pm
Location: TBA

Dr. Stephen Fodor is the Founder and Chairman of Affymetrix. He and his colleagues invented and produced the world's first massively parallel system for measuring the genetics of an organism. In the late 1980's and early 1990's, Dr. Fodor led the development of the DNA chip, or microarray, at the Affymetrix Research Institute in Palo Alto, California and founded Affymetrix in 1993 to commercialize the technology. The scientific methods and products have played a pivotal role in understanding the functioning of the genome in basic and clinical research, discovery and mapping of human variation, and are currently being developed into diagnostic devices. Results using the technology are now reported in over 23,000 peer-reviewed scientific publications. Dr. Fodor has received numerous honors and awards for this work, including the Newcomb-Cleveland Award from the American Association for the Advancement of Science, The Jacob Heskel Gabbay Award in Biotechnology and Medicine, The Takada Foundation Award, The Economist Award in Nanotechnology and The Association for Laboratory Automation Achievement Award. He is an author of 58 scientific articles, is a member of the National Academy of Engineering, and a Trustee of the Carnegie Institution of Science.

Dr. Fodor will present a short history of Affymetrix, the technology behind the company, how the business opportunity was developed, how the science was financed and how the company evolved from a few employees and no revenue, to a successful biotechnology company with thousands of customers, multiple competitors, and over 400 million dollars per year revenues.

He will share personal stories about successes and failures, lessons learned and engage you in a discussion about the transitions from academia to industry, identifying opportunities, considerations about starting a new venture and the current entrepreneurial climate in biotechnology.